Pns52 Assessment of the Impact of the Level of Asmr on the Drug's Price and Its Negotiation Time With the Health Authorities in Treatments That Benefited From the French Early Access Program

Abstract

methods has intrinsic limitations linked to the many assumptions that need to be made. Nonetheless, it provides to be a valuable tool in assessing portfolio assets. Our experience in access made us aware of the healthtechnology-valuation hurdles that may affect the cash flows generated by a patented asset over its lifetime. Thus, we suggest to shift the access mindset to earlier decision points in the drug development process. In this fashion, more valuable assets are likely to be brought to the clinic over the next decade.